Although I'm here BRAGGING about all the money I've made shorting this stock under the name redhaw, let me give you a MATH lesson on what WOULD have happened if I had actually shorted 250,000 shares at $1.15 as I claimed I did 12 weeks ago. Not only would I have paid $57,600 in interest to date, I'D STILL be upside DOWN by .42 cents/share. NOW do you see why I'm trying so hard to get you to sell???
Here's ANOTHER math lesson for you. Under my alias Redhaw, I claimed to have 250,000 short shares that I picked up 8 WEEKS ago at $1.15. At a CONSERVATIVE estimate of 60% interest, I've already lost $57,600 and I STILL haven't covered. Talk about being a BAGHOLDER!!! HAW HAW HAW HAW HAW HAW!!!!!
How about a COMPARISON! I know how much BAGHOLDERS just LOVE it when I do COMPARISONS! Lets START by looking at script numbers FOUR MONTHS after the SECOND launch of afizle:
Nrx = 152
Refills = 153
Trx = 305
Now THOSE came from those NASTY 40 CONTRACT reps who ALLEGEDLY weren't DEDICATED enough for MNKD to KEEP!
INSTEAD, MNKD hired OVER 100 of their OWN reps to insure they're "dedicated" and now SIX MONTHS after the THIRD launch, the script numbers are:
Nrx = 197
Refills = 173
Trx = 370
NOW for a PROPER comparison, let's LOOK the numbers in terms of script production PER REP! For the SECOND launch:
Nrx = 3.8
Refills = 3.8
Trx = 7.6
For the THIRD launch:
Nrx = 2.0
Refills = 1.7
Trx = 3.7
ALLOW me to TRANSLATE for the BAGHOLDERS who are generally too STUPID to understand RATIOS!
The DEDICATED reps are generating only FIFTY PERCENT of what the UNDEDICATED reps were achieving!
Got that? Each DEDICATED rep is generating only about HALF as many scripts as did each UNDEDICATED rep.
And THOSE undedicated reps DIDN'T have the "help" of Damon Dash, Charles Mattocks, and Jeff Dachis out promoting afrezza for them! And I BET that once Mannkind STOPS handing out VOUCHERS for FREE $700 titration paks, that comparison will get even WORSE.
Take away the 10 mil they owe Deerfield pretty soon and the 10 mil in cash they have to have at the end of each month and MNKD has only about TWELVE million in cash -- only about SIX more weeks worth! They better get that MASSIVE DILUTION on the ball before it's TOO LATE!
MannKind: Still Highly Speculative
Scripts for week ending August 11 were at 370. Refills hit new high. Revenue well below company guidance.
I JUST don't understand it. I post, and post, and post, and post, day and night, 24/7 to scare, intimidate, insult, and whatever else my boss can dream up to get you to SELL this stock. And yet, NO ONE is SELLING!!??!! I can't BELIEVE that I SUCK at this job even more than I sucked at music. God, please end this miserable existence.
LOh, LOOK! I found another BAGHOLDER no DOUBT celebrating an ANNIVERSARY:
"...you will notice that I am taking advantage of the current price to increase the number of shares we own in both Portfolios by another 20% this month in anticipation that by this time next month, the outlook will be much rosier for MannKind."
That means that "Nate" -- aka "BLACK DEATH" when it comes to MNKD stock -- is DOWN around SEVENTY PERCENT on that investment! I TRIED to tweet him CONGRATULATIONS but don't you know he BLOCKED me! I can't imagine WHY!
*** The following commentary was published for subscribers of Nate’s Notes in Issue #259 on August 12, 2016, and reflects our opinions of both the market and MannKind as of that date. *** Stocks aren’t lottery tickets. There’s a company attached to e
FAKE NEWS NEW SCRIPT NUMBERS:
Nrx = 197
Refills = 173
Trx = 370
I say FAKE since it is NOW known that MNKD reps are handing out VOUCHERS fore FREE titration paks worth $700 in order to try and BOOST script numbers!
Jerry Just Jerry
Redhaw once again here all weekend along. This guy has no family, friends, and by no means NO MONEY
Want to see FAILURE in motion? Let's COMPARE the NEW script numbers for some diabetic drugs for JUST the EIGHTH week after their original launch:
1st launch 223
2nd launch 135
And NOW afizzle is SIX MONTHS post its THIRD launch and has been on the market OVER Two and a HALF YEARS, yet LATEST new scripts were Nrx = 197!
Do these numbers REALLY need any additional commentary?
WoW -- Kinda like what's going to happen when Investors in David Kliff's planning firm from Chicago wake up one day shorting mannkind and stock goes from $1.50 to $50 bucks. Hey David, I just lost my a&^%$%. ---
How about some more MATH!!! I know BAGHOLDERs really get THRILLED when I start doing MATH! CONSIDER that the LAST quarter of 2016, when MNKD had all FORTY of those nasty "non-dedicated" contract reps, the net revenue was about 1.2 million.
Accorsing to the LAST earnings report, NOW that they have OVER ONE HUNDRED fully DEDICATED reps "hitting the concrete" pushing afizzle, the net revenues are 1.5 million.
SO the addition of SIXTY "dedicated" reps amounted to a whopping $300,000 increase in revenues from what the UNDEDICATED reps produced!
It's even WORSE when you consider those nasty contract reps DIDN'T have Damon DUMBash or Charles BUTocks or Jeff Dachis out pumping afizzle!
See where I'm going with this?
BAGHOLDERS can BET that Solomon Steiner -- the INVENTOR of technosphere -- KNEW how BAD the LATEST NEW SCRIPT NUMBERS:
Nrx = 197
Refills = 173
Trx = 370
...would be! yeah! He LEFT Mannkind around 2003, 10 YEARS after selling them the technology, and then started his own company -- "Biodel" -- for delivering -- are you ready for this? -- an "ultra-rapid-acting concentrated insulin" using an INJECTION! REALLY now? Go figure!
He also later started Perosphere which ALSO does NOT use inhalation to deliver ITS product.
What does THAT tell you about what HE thinks of inhaled medications?
I mean, if the INVENTOR not ONLY abandoned ship TWELVE YEARS AGO, but went on to form TWO companies, NEITHER of which use technosphere, that OUGHT to tell you what the INVENTOR himself thinks about the potential of TS and afizzle! Right?
Time for an ANNIVERSARY! BAGHOLDERS just LOVE their ANNIVERSARIES! Yeah! Justa YEAR ago on the tudiabetes forum:
And the FUNNY thing is that when THAT was written, MNKD was trading at $4.00 a share! and yet it STILL managed to LOSE yet another SEVENTY PERCENT since then! Go FIGURE!
MannKind (Afrezza) stock is in a death spiral: bad sign
Investors are exiting MannKind (MNKD) stock in droves as the company takes over from Sanofi the marketing of Afrezza. Share price is down 80% over the past 52 weeks to well under $1. It's currently at 70 cents. One glaring problem is that the comp
By the way - that last post I made about Solomon? That marks the 182nd time I've posted that same BULL SSHSHHTTTTT
Want to HEAR Failure in MOTION? Just check out my music career. Why do you think I'm here all day and night?
Bringing back MEMORIES from a YEAR ago for the BAGHOLDERS:
Personally, I LOVED the "editors note" at the TOP of the article:
"Editor's note: Updated to correct a mischaracterization of MannKind's assistance to doctors who want to conduct lung testing on prospective Afrezza patients.The company helps physicians identify spirometers suitable for the testing. It does not purchase the machines for doctors, nor is it involved in such transactions in any way."
HAW!!! I STILL find that simply HILARIOUS!!! They were going to HELP "physicians identify spirometers suitable for the testing"?? THAT does so SOUND like a TYPICAL Mannkind " solution, doesn't it?
I wonder how many BAGHOLDERS think THAT was a "solution"?
MannKind turns to digital, social media to spread the word on Afrezza's relaunch | FiercePharma
Skeptics say MannKind can't succeed with its inhaled insulin Afrezza, not when Sanofi failed. The smaller drugmaker has been toiling to probe them wrong, with a sales-and-marketing strategy on a shoestring budget--at least compared with the typical B
Label change then buyout for miracle treatment. $168 per share. JMHO